Navigation Links
DrugRisk Update: Bayer Adds Gallbladder Claims to Yaz Settlements
Date:4/2/2013

New York, NY (PRWEB) April 02, 2013

The birth control safety advocates at DrugRisk.com are announcing new information on the site for women who have taken the drugs Yaz or Yasmin. The manufacturer, Bayer, will now compensate certain patients who allege gallbladder injuries, in addition to the ongoing settlements for blood clots*.

The goal of DrugRisk is to improve patient safety by providing the latest warnings, recalls, studies and litigation news. Visitors can learn if others have experienced similar side effects and decide if they need legal help to join current litigation.

The resource center has learned that Bayer will designate $24 million to compensate patients who allege gallbladder injuries after taking Yaz or Yasmin*. While this could affect as many as 8,000 patients, payouts are only estimated at $2,000 to $3,000*.

Thousands more have filed a Yaz lawsuit alleging blood clot injuries, which were consolidated to a special federal Multi-District Litigation court in Illinois. The case is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).

Experts with the British Medical Journal and FDA have alerted patients that birth control pills containing drospirenone, like Yaz and Yasmin, can increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%**.

DrugRisk has obtained the latest financial reports from Bayer, which states the company has spent nearly $1 billion to settle around 4,800 claims alleging blood clot injuries like deep vein thrombosis (DVT) or pulmonary embolism***. The average amount paid to patients for these claims is over $208,000, much higher than for gallbladder injuries.

Lawyers are still helping those who suffered a blood clot, DVT, stroke or pulmonary embolism after taking Yaz or Yasmin learn their legal options for a Yaz settlement. Anyone affected is urged to contact the DrugRisk Resource Center or speak with a lawyer.

Due to the specialized nature of federal MDL drug injury cases, DrugRisk urges patients to seek a lawyer with experience in this litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.

For more information on the research, side effects, a possible Yaz recall and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*newsandinsight.thomsonreuters.com/Legal/News/2013/03_-_March/Bayer_agrees_to_settle_Yasmin,_Yaz_gallbladder_lawsuits/
**British Medical Journal, October 25, 2011, University of Copenhagen; FDA, October 27, 2011, "Combined Hormonal Contraceptives and the Risk of Cardiovascular Disease Endpoints"
***Bayer 2012 Annual Report, Consolidated Financial Statement, Legal Notes, February 28, 2013

Read the full story at http://www.prweb.com/releases/yaz-settlement/yaz-recall/prweb10589403.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Center Announces Court Postponement of NuvaRing Lawsuits
2. DrugRisk Announces Alternative to Mirena IUD May Be Available Soon
3. DrugRisk Announces Updated Information on Mirena Lawsuits
4. DrugRisk Adds Latest Health Warnings and Lawsuit Updates for Yaz
5. DrugRisk Announces New Pradaxa Health Warning From Australia
6. DrugRisk Update: NuvaRing Lawsuit Trials to Begin This Year
7. DrugRisk Update: Court Allows Charges of Prior Fraud Into Pradaxa Lawsuit
8. DrugRisk Pradaxa Lawsuit Update: Court Denys Boehringer’s Protective Order Request
9. DrugRisk Pradaxa Update: Litigation Grows As New Study Adds to Risks
10. DrugRisk Update: Bayer Discloses $500 Million Remaining for Yaz Lawsuits
11. DrugRisk Update: Evidence Submitted in Actos Lawsuit Suggests Drug Maker Knew of Cancer Risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica ... in thought leadership , media relations, social media, content marketing and SEO, ... be powered through Act-On, an intuitive marketing automation platform. , Rosica will now ...
(Date:2/23/2017)... ... 23, 2017 , ... On February 22, 2017 the U.S. ... to withdraw previous guidance issued by the Obama Administration requiring schools to treat ... 2016 by the Obama Administration came in response to a growing number of ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The American Cleft ... ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. , ... exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information Services ... Institute for Health and Care Excellence (NICE) framework. The agreement allows purchasers ... (NHS) to search, order and purchase medical and healthcare-related content through GOBI ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... provides drug pricing data and benchmarks in the global Urinary Incontinence ... What are the key drugs marketed for Urinary Incontinence ...
(Date:2/23/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device company ... the urology market, will release financial results for the ... before the market open on Thursday, March 9, 2017. ... call and webcast to discuss its financial results the ... a.m. Eastern Time (10:00 a.m. Central Time). Darin ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
Breaking Medicine Technology: